02696nas a2200409   4500000000100000008004100001100001800042700002300060700001200083700001400095700001500109700001700124700001400141700001300155700001400168700001200182700001200194700001400206700001400220700001500234700001500249700001300264700001400277700001500291700001700306700001500323700001500338700001400353700001300367700001600380700001600396700001400412245018400426250001500610520161000625020005102235       2015                            d1 aRanasinghe I.1 aAliprandi-Costa B.1 aChew D.1 aFrench J.1 aBrieger D.1 aTroughton R.1 aGamble G.1 aWhite H.1 aBriffa T.1 aCarr B.1 aHyun K.1 aAstley C.1 aHowell T.1 aLintern K.1 aHammett C.1 aEllis C.1 aDevlin G.1 aElliott J.1 aLefkovitz J.1 aBloomer S.1 aFarshid A.1 aMatsis P.1 aHamer A.1 aWilliams M.1 aHorsfall M.1 aRedfern J00aA comparison of the management and in-hospital outcomes of acute coronary syndrome (ACS) patients in Australia and New Zealand: Results from the binational SNAPSHOT ACS 2012 audit  a2015/03/133 a<p>
AIMS: We aimed to assess differences in patient management, and outcomes, of Australian and New Zealand patients admitted with a suspected or confirmed acute coronary syndrome (ACS). METHODS: We used comprehensive data from the binational Australia and New Zealand ACS 'SNAPSHOT' audit, acquired on individual patients admitted between 00.00 hours on 14 May 2012 to 24.00 hours on 27 May 2012. RESULTS: There were 4387 patient admissions, 3381 (77%) in Australia and 1006 (23%) in New Zealand; Australian patients were slightly younger (67 vs 69 years, p=0.0044). Of the 2356 patients with confirmed ACS, Australian patients were at a lower cardiovascular risk with a lower median GRACE score (147 vs 154 p=0.0008), but as likely to receive an invasive coronary angiogram (58% vs 54%, p=0.082), or revascularisation with PCI (32% vs 31%, p=0.92) or CABG surgery (7.0% vs 5.6%, p=0.32). Of the 1937 NSTEMI/UAP patients, Australian patients had a shorter time to angiography (46 vs 67 hours, p&lt;0.0001). However, at discharge, Australian NSTEMI/UAP survivors were less likely to receive aspirin (84% vs 89%, p=0.0079, a second anti-platelet agent (57% vs 63%, p=0.050) or a beta blocker (67% vs 77%, p=0.0002). In hospital death rates were not different (2.7% vs 3.2%, p=0.55) between Australia and New Zealand. CONCLUSIONS: Overall more similarities were seen, than differences, in the management of suspected or confirmed ACS patients between Australia and New Zealand. However, in several management areas, both countries could improve the service delivery to this high-risk patient group.
</p>
  a1445-5994 (Electronic)<br/>1444-0903 (Linking)